methotrexate (NovoBioJect) / Amplio Pharma - LARVOL DELTA

Amplio Pharma Reports Positive Early Clinical Results for NovoBioJect, Designed to Make the World’s Most-Used Rheumatoid Arthritis Drug Work for More Patients (GlobeNewswire) - "Amplio Pharma...announced positive results from its Phase 1b study of NovoBioJect in patients with RA....First clinical proof of principle. In an exploratory pharmacokinetic study in rheumatoid arthritis patients, a single dose of NovoBioJect led to 38% more active methotrexate inside the immune cells that drive inflammation, compared with methotrexate alone. Favorable single-dose safety profile. No adverse events other than mild, dose-dependent injection-site reactions were observed....The results de-risk the next step: a Phase 2a proof-of-concept study in the Netherlands, to be funded by a Series A financing of approximately €10 million that Amplio is now initiating."

New P2a trial • P1 data • Rheumatoid Arthritis